Recruiting soon

GALLOP2Semaglutide for Acute Ischemic Stroke After Endovascular Treatment

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Semaglutide 0.5 mg

+ Standard medical treatment

DrugOther
Who is being recruted

Ischemic Stroke+5

+ Brain Diseases

+ Cardiovascular Diseases

Over 18 Years
+22 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 3
Interventional
Study Start: February 2025
See protocol details

Summary

Principal SponsorWei Hu
Study ContactWei Hu, MD, PhD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2025

Actual date on which the first participant was enrolled.

This clinical trial is exploring whether the medication semaglutide can help improve recovery for people who have had a type of stroke known as acute ischemic stroke, which is caused by a blockage in a large blood vessel in the brain. The study focuses on individuals who have undergone a medical procedure called endovascular treatment to remove the blockage. The trial is important because it aims to find out if semaglutide can enhance patients' ability to recover better in the 90 days following their stroke, potentially offering a new way to improve outcomes for stroke patients. Participants in the study will receive an injection of 0.5mg semaglutide before and one week after their endovascular treatment, or they may receive the treatment without the semaglutide injection for comparison. Throughout the study, participants will undergo blood tests and multiple neurological assessments to monitor their progress. Brain imaging tests, including CT scans and MRIs, will also be conducted after the treatment to evaluate changes and recovery in the brain. The study measures the effectiveness and safety of semaglutide by comparing the functional recovery of patients who received the medication against those who did not.

Official TitleGlucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
NCT06788626
Principal SponsorWei Hu
Study ContactWei Hu, MD, PhD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

390 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Ischemic StrokeBrain DiseasesCardiovascular DiseasesCentral Nervous System DiseasesCerebrovascular DisordersNervous System DiseasesVascular DiseasesStroke

Criteria

8 inclusion criteria required to participate
LVO stroke at terminal ICA, M1 or dominant M2 with an LKW-to-randomization ≤24 hours
Age ≥ 18 years old
National Institute of Health Stroke Scale ≥ 6 at the time of brain imaging
Acute LVO stroke due to thromboembolism or intracranial stenosis
Show More Criteria
14 exclusion criteria prevent from participating
Use of intravenous thrombolytic therapy (alteplase or tenecteplase)
Pre-stroke mRS > 2 for patients <80 years and > 1 for patients ≥ 80 years old
Intracranial hemorrhage or brain tumour on initial imaging (except small meningiomas)
Simultaneous occlusion of bilateral anterior circulation, or both anterior and posterior circulation
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Participants will receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT. Additionally, they will receive antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.

Group II

Placebo
Standard medical management. Participants will receive EVT, antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

The First Affiliated Hospital of University of Science and Technology of China

Hefei, ChinaOpen The First Affiliated Hospital of University of Science and Technology of China in Google Maps
Recruiting soonOne Study Center